ArticleCritical care medicine2017
Long-Term Survival in Adult Patients With Severe Acute Lung Failure Receiving Veno-Venous Extracorporeal Membrane Oxygenation.
Article in Critical care medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Long-term outcomes of patients supported with extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis.Intensive care medicine · 2024Pooled it
- ECMO for patients with obesity: evidence and practice.Intensive care medicine · 2026Review
- Incidence and impact of intracranial complications in patients undergoing extracorporeal membrane oxygenation treatment.Brain & spine · 2026Article
- Outcomes of transplant recipients on ECMO for COVID-19 respiratory failure: an ELSO registry study.Critical care (London, England) · 2025Article
- Long-term health related quality of life in adult extracorporeal membrane oxygenation survivors: a single-centre, cross-sectional study.BMC public health · 2024Article
- Article
- Extracorporeal Membrane Oxygenation for Septic Shock in Adults and Children: A Narrative Review.Journal of clinical medicine · 2023Review
- Long-Term Outcomes of Extracorporeal Life Support in Respiratory Failure.Journal of clinical medicine · 2023Review
- Extracorporeal Membrane Oxygenation for Septic Shock in Children.ASAIO journal (American Society for Artificial Internal Organs : 1992) · 2022Article
- [ECMO treatment in acute lung failure : Who profits?]Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2020Review
- Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients.Annals of intensive care · 2019Article
- Cost-effectiveness in extracorporeal life support in critically ill adults in the Netherlands.BMC health services research · 2018Observational
- The effect of multidisciplinary extracorporeal membrane oxygenation team on clinical outcomes in patients with severe acute respiratory failure.Annals of intensive care · 2018Article
- Life span of different extracorporeal membrane systems for severe respiratory failure in the clinical practice.PloS one · 2018Article
- ECMO-treatment in patients with acute lung failure, cardiogenic, and septic shock: mortality and ECMO-learning curve over a 6-year period.Journal of intensive care · 2018Article
- Activated Partial Thromboplastin Time and Anti-IIa Monitoring in Argatroban Anticoagulation in COVID-19 Patients on Venovenous Extracorporeal Membrane Oxygenation.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisObservational
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess long-term survival in adult patients with severe acute lung failure receiving veno-venous extracorporeal membrane oxygenation and explore risk factors for long-term mortality.
designSingle-center prospective cohort study.
settingUniversity Hospital Regensburg, Germany. PATIENTS: All primary cases supported with veno-venous extracorporeal membrane oxygenation from 2007 to 2016 (n = 553).
interventionsNone. MEASUREMENTS AND MAIN
resultsPatients were followed until January 2017. Long-term survival and predictors of long-term mortality were assessed using Kaplan-Meier survival analyses and Cox proportional hazards modeling, respectively. Two hundred eighty-six patients (52%) died during follow-up (mean follow-up 4.8 yr). Two hundred seventeen patients (39%) died during hospitalization, whereas another 69 patients (12%) died during later follow-up. Among hospital survivors, the 1-month, 3-month, 1-year, and 5-year survival rates were 99%, 95%, 86%, and 76%, respectively. Higher age, immunocompromised status, and higher Sequential Organ Failure Assessment scores were associated with long-term mortality, whereas patients with out-of-center cannulation showed improved long-term survival. Due to nonproportional hazards over time, the analysis was repeated for hospital survivors only (n = 336). Only age and immunocompromised state remained significant predictors of late mortality among hospital survivors. Lower Glasgow Outcome Scale at hospital discharge and the University Hospital Regensburg pre-extracorporeal membrane oxygenation score for predicting hospital mortality in veno-venous extracorporeal membrane oxygenation patients before extracorporeal membrane oxygenation initiation were associated with late mortality in hospital survivors (p < 0.001).
conclusionsWhereas acute illness factors may be important in prediction of hospital outcomes in veno-venous extracorporeal membrane oxygenation patients, they do not determine late mortality in hospital survivors. Preexisting morbidity and functional ability at hospital discharge may be important determinants of long-term survival in veno-venous extracorporeal membrane oxygenation patients.
Indexed as
Identifiers
28787296What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.